Locations:
Search IconSearch
August 17, 2021/Cancer

Case Report: Endoscopic Submucosal Dissection for Colorectal Polyp

Endoluminal surgery provides new treatment options

Emre Gorgun, MD

A 59-year-old woman received a positive result on a self-administered at-home screening test used to detect neoplasia-associated DNA markers and occult hemoglobin in patients’ stool. She had no significant medical or surgical history, was not taking antiplatelets or anticoagulants, and reported no family history of colorectal malignancy.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cleveland Clinic colorectal surgeon Emre Gorgun, MD, Director for Lower GI of the Digestive Disease & Surgery Institute’s Endoluminal Surgery Center, performed a full colonoscopy, which is recommended for patients with positive self-test results. The procedure identified a large 10-cm by 9-cm multilobulated, frond-like polypoid lesion in the patient’s ascending colon, 7-10 cm from the ileocecal valve. The polyp was nonobstructive but occupied approximately two-thirds of the luminal circumference.

Importantly, the lesion was not affixed or tethered to the underlying bowel wall, a finding that suggested a benign condition; however, Dr. Gorgun was concerned that the interior portion of the lesion could contain an invasive cancer. A biopsy revealed fragments of a benign tubulovillous adenoma polyp with malignant potential. An abdominal CT was unremarkable and did not demonstrate a colonic lesion or any evidence of metastatic cancerous spread.

The patient was presented with two treatment options: endoscopic excision using advanced resection techniques or formal surgical bowel resection.

Recent technological advances have made it possible to remove precancerous, cancerous and complex polypoid lesions of the gastrointestinal tract endoscopically, rather than using traditional surgical bowel resection. This new field of endoluminal surgery, which is only available at advanced tertiary care centers such as Cleveland Clinic, avoids extensive surgery and allows patients to keep their native organs and have an improved quality of life. Endoluminal surgery involves procedures such as endoscopic submucosal dissection, complex endoscopic mucosal resection, endoscopic full-thickness resection and submucosal tunneling endoscopic resection.

Advertisement

Cleveland Clinic Quick Case: Endoluminal Surgery (Graphic)

Details of the endoscopic approach

Dr. Gorgun’s patient chose to undergo endoscopic submucosal dissection (ESD) of the lesion. Following full bowel preparation, the patient was administered preoperative intravenous antibiotics for infection prophylaxis and subcutaneous heparin to reduce the risk of a thromboembolic event. The patient was placed under general anesthesia with complete muscle relaxation, which is standard for ESD.

“The first step in the procedure involves creating a ‘lift’ of submucosal tissue around the lesion by injecting the submucosal layer with a gelatin-based colored dye solution,” explains Dr. Gorgun. “In this case, we used a proximal-to-distal approach to inject 30-40 mL of a viscous submucosal gel that separates the lesion from the underlying muscular layer of the bowel wall and allows full endoscopic excision of the entire specimen with layers deep enough for full pathological assessment.”

Working distally to proximally — at times with the endoscope in the retroflexed position — Dr. Gorgun excised the lesion en bloc using a 2-mm electrosurgical knife. The tool’s pin-tip point enabled accurate dissection between the layers of the bowel wall. “It is important in dissection to achieve adequate margins around the specimen,” Dr. Gorgun says.

The 10-cm by 10-cm lesion was retrieved using an endoscopic net device and sent for histopathological analysis. Dr. Gorgun inspected the resected margins for hemostasis and any full-thickness or muscular-layer breaches requiring repair. Three 17-mm hemoclips were applied apposed to the underlying muscular layer.

Advertisement

A successful outcome

The patient was discharged to home on the day of the procedure and subsequently could tolerate a full diet. She recovered without complications and experienced no abdominal pain or rectal bleeding.

Final histopathology of the specimen showed a tubulovillous adenoma with clear margins and no evidence of underlying dysplasia. The patient did not require further treatment and was scheduled for a repeat colonoscopy in 6 months for surveillance.

Figure 1. Frond-like polypoid lesion in the ascending colon.

Frond-like polypoid lesion in the ascending colon.

Figure 2. Non-obstructive lesion occupying more than two-thirds of the luminal circumference.

Figure 2. Non-obstructive lesion occupying more than two-thirds of the luminal circumference.

Figure 3. Endoluminal surgery using a 2-mm electrosurgical knife.

Endoluminal surgery using a 2-mm electrosurgical knife.

Figure 4. Submucosal dissection with the endoknife.

Submucosal dissection with the endoknife.

Figure 5. Retrograde view of the lesion.

Retrograde view of the lesion.

Figure 6. View of the completely resected lesion site.

View of the completely resected lesion site.

Figure 7. Endoscopic clip closure of the resection site.

Endoscopic clip closure of the resection site.

Figure 8. En-bloc removed specimen pinned on a cork board for histopathology analysis.

En-bloc removed specimen pinned on a cork board for histopathology analysis.

Slide 1/8

Advertisement

Related Articles

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Dr. Gerds
December 8, 2025/Cancer/News & Insight
AI Screening Platform Accelerates Trial Recruitment in Polycythemia Vera

AI-driven tools can streamline enrollment and improve efficiency across clinical trials.

PET scan after CAR T-cell therapy
December 5, 2025/Cancer/Blood Cancers
Case Study: Overcoming Communication Barriers to Enroll Patient in CAR T-Cell Therapy Clinical Trial

Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel

Dr. Roesch
November 28, 2025/Cancer
Management of Pregnancy-Associated Breast Cancer (Podcast)

Supporting patients during pregnancy and beyond

Ad